AVEO/Astellas 2012 filing for tivozanib as it beats Nexavar in Ph III kidney cancer trial
This article was originally published in Scrip
Tivozanib, AVEO Pharmaceuticals' VEGF inhibitor partnered with Astellas Pharma, was better than Bayer HealthCare/ Onyx Pharmaceuticals ' Nexavar (sorafenib) in prolonging progression-free survival in patients with advanced renal cell carcinoma (RCC) in a Phase III head-to-head study, top-line data show. AVEO and Astellas said the trial results mean they will submit the drug for marketing approval in the US and Europe this year.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.